Investor Presentaiton

Addressing high unmet medical need in Oncology & Hematology Oncology Bladder $5B+ H&N $3B+ Hematology CLL $7B+ 2030 2023 $85B+ Lung $33B+ Renal $9B+ Liver $3B+ Melanoma $9B+ Ovarian $3B+ AML $1B+ MF $2B+ MDS $1B+ CHL $2B+ $49B+ MM $22B+ CRC $6B+ GI $1B+ NHL $14B+ Prostate $14B+ Renal $8B+ Bladder $10B+ H&N $5B+ Liver $4B+ CLL $11B+ Melanoma $14B+ AML $10B+ Ovarian $9B+ MM $31B+ $140B+ Lung $61B+ GI $4B+ Prostate $20B+ CRC $7B+ MF $3B+ CHL $3B+ MDS $6B+ $90B+ NHL $27B+ ll Bristol Myers Squibb™ Source: EvaluatePharma estimates; totals may not add due to rounding Not for Product Promotional Use 148

View entire presentation